Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.74 |
| ▸ | PTGS1 known ✓ | P23219 | 7/20 | 0.61 |
| ▸ | PTGS2 known ✓ | P35354 | 7/20 | 0.61 |
| ▸ | MGLL | Q99685 | 10/20 | 0.74 |
| ▸ | FAAH | O00519 | 5/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.74 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | XBP1 | P17861 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3402339 | 1.00 | MGLL (0.74) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL9999878 | 0.98 | MGLL (0.77) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL25586313 | 0.98 | MGLL (0.77) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL25586309 | 0.98 | MGLL (0.77) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL25586311 | 0.98 | MGLL (0.77) | MGLLFAAHALDH1A1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL1726633 | 0.98 | MGLL (0.73) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL338631 | 0.98 | MGLL (0.77) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL25586310 | 0.98 | MGLL (0.77) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL4174559 | 0.98 | MGLL (0.77) | MGLLFAAHALDH1A1LMNAMAPT | |
| SCHEMBL25586312 | 0.98 | MGLL (0.77) | MGLLFAAHALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683675-A2 | DLL3 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4637833-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | Genentech, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024206573-A9 | AMHRII ANTIBODY-DRUG CONJUGATES AND USES THEREOF | EXELIXIS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250122280-A1 | ANTI-Ly6E ANTIBODIES, IMMUNOCONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4519322-A1 | ANTI-LY6E ANTIBODIES, IMMUNOCONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119137157-A | Anti-Ly 6E antibodies, immunoconjugates and uses thereof | 基因泰克公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024206573-A2 | AMHRII ANTIBODY-DRUG CONJUGATES AND USES THEREOF | EXELIXIS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024197140-A2 | DLL3 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | EXELIXIS, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20240285788-A1 | CONJUGATE OF ANTIBODY AND FUNCTIONAL SUBSTANCE OR SALT THEREOF, AND ANTIBODY DERIVATIVE AND COMPOUND USED IN PRODUCTION OF THE SAME OR SALTS THEREOF | AJINOMOTO CO., INC. (JP) | 2024-08-29 | — | — | US | disclosed |
| US-20240269311-A1 | REGIOSELECTIVE CONJUGATE OF ANTIBODY AND FUNCTIONAL SUBSTANCE OR SALT THEREOF, AND ANTIBODY DERIVATIVE AND COMPOUND USED IN PRODUCTION OF THE SAME OR SALTS THEREOF | AJINOMOTO CO., INC. (JP) | 2024-08-15 | — | — | US | disclosed |
| EP-1066523-A2 | CONFIRMATORY ASSAYS FOR SMALL MOLECULE DRUGS | MICROGENICS CORPORATION (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999042840-A1 | IMMUNOASSAYS FOR DETERMINATION OF LSD AND LSD METABOLITES | MICROGENICS CORPORATION (US) | 1999-08-26 | — | — | WO | disclosed |
| WO-1998026644-A9 | CONFIRMATORY ASSAYS FOR SMALL MOLECULE DRUGS | MICROGENICS CORP (US) | 1999-04-08 | — | — | WO | disclosed |
| US-5843682-A | N-1-carboxyalkyl derivatives of LSD | BOEHRINGER MANNHEIM CORPORATION (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0880029-A1 | Immunoassay for glucuronide metabolites of LSD | BOEHRINGER MANNHEIM CORPORATION (US) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998026644-A2 | CONFIRMATORY ASSAYS FOR SMALL MOLECULE DRUGS | MICROGENICS CORPORATION (US) | 1998-06-25 | — | — | WO | disclosed |
| EP-0830370-A4 | — | — | 1998-03-25 | — | — | EP | disclosed |
| EP-0830370-A1 | N-1-CARBOXYALKYL DERIVATIVES OF LSD | BOEHRINGER MANNHEIM CORPORATION (US) | 1998-03-25 | — | — | EP | disclosed |
| WO-1997019100-A1 | N-1-CARBOXYALKYL DERIVATIVES OF LSD | BOEHRINGER MANNHEIM CORPORATION (US) | 1997-05-29 | — | — | WO | disclosed |
| US-5595741-A | Aminoalkylmaleimides and hapten and antigen derivatives derived therefrom as well as conjugates with peptides or proteins | BOEHRINGER MANNHEIM GMBH (DE) | 1997-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122280-A1 | ANTI-Ly6E ANTIBODIES, IMMUNOCONJUGATES, AND USES THEREOF | LY6K, SELE, CXCR3 | HSP90AA1 1264/4885PTGS1 4426/4885PTGS2 4343/4885 |
| US-20240269311-A1 | REGIOSELECTIVE CONJUGATE OF ANTIBODY AND FUNCTIONAL SUBSTANCE OR SALT THEREOF, AND ANTIBODY DERIVATIVE AND COMPOUND USED IN PRODUCTION OF THE SAME OR SALTS THEREOF | ARGLU1, VSIG8, ARG1 | HSP90AA1 1645/4885PTGS1 2921/4885PTGS2 3896/4885 |
| US-20240285788-A1 | CONJUGATE OF ANTIBODY AND FUNCTIONAL SUBSTANCE OR SALT THEREOF, AND ANTIBODY DERIVATIVE AND COMPOUND USED IN PRODUCTION OF THE SAME OR SALTS THEREOF | IGLV6-57, FCGR3B, IGSF11 | HSP90AA1 684/4885PTGS1 939/4885PTGS2 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.